Dystrophic epidermolysis bullosa

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

10 events
Jan 2026A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

Xinnate AB — PHASE2

TrialRECRUITING
Jan 2026GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment

CHU de Quebec-Universite Laval — PHASE1, PHASE2

TrialRECRUITING
Aug 2025Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

M. Peter Marinkovich — PHASE1, PHASE2

TrialRECRUITING
Aug 2025DEB-BACE for Primary Lung Cancer: A Retrospective, Single-Arm, Multicenter Study on Efficacy and Safety

Gang Wu, MD

TrialNOT YET RECRUITING
Jul 2025Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM

Peking University Cancer Hospital & Institute

TrialNOT YET RECRUITING
Jul 2025Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

M. Peter Marinkovich — PHASE1, PHASE2

TrialNOT YET RECRUITING
Jun 2025A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc. — PHASE3

TrialRECRUITING
Apr 2025

Zevaskyn: FDA approved

treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB)

FDAcompleted
Apr 2025A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa

Chiesi Farmaceutici S.p.A. — PHASE3

TrialRECRUITING
Mar 2025Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin

Stanford University — PHASE2

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

7 programs

FINANCIAL LANDSCAPE SUMMARY

7

Total programs

7

Open now

2

Copay cards

4

Travel grants

Copay Assistance2

VYJUVEK

Krystal Biotech

OpenContact for detailsApply ↗

ZEVASKYN

Unknown

OpenContact for details

Patient Assistance Programs1

Filsuvez

Chiesi USA, Inc.

OpenContact for detailsApply ↗

Travel Grants4

Chiesi Total Care FILSUVEZ Copay Program

OpenContact for detailsApply ↗

Epidermolysis Bullosa Financial Assistance Program

The Assistance Fund

OpenContact for detailsApply ↗

The Assistance Fund: Epidermolysis Bullosa

The Assistance Fund

OpenContact for detailsApply ↗

The Assistance Fund: Epidermolysis Bullosa Financial Assistance Program

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

3 FDA-approved

Vyjuvek

(VYJUVEK)Orphan drug

Krystal Biotech, Inc.

12.1 Mechanism of Action Dystrophic epidermolysis bullosa (DEB) is caused by mutation(s) in the COL7A1 gene, which results in reduced or absent levels...

Approved Sep 2025FDA label ↗

Zevaskyn

(PRADEMAGENE ZAMIKERACEL)Orphan drug

Abeona Therapeutics Inc.

12.1 Mechanism of Action In patients with recessive dystrophic epidermolysis bullosa (RDEB), both copies of the COL7A1 gene are mutated, resulting in ...

Approved Apr 2025FDA label ↗

Filsuvez

(BIRCH TRITERPENES)Orphan drugstandard

Chiesi USA, Inc.

12.1 Mechanism of Action The mechanism of action of FILSUVEZ in the treatment of wounds associated with epidermolysis bullosa is unknown.

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

20 active trials
5Phase 3
2Phase 2
1Phase 1
6Unknown
5PHASE1, PHASE2
1EARLY_PHASE1
20Total recruiting
Search clinical trials for Dystrophic epidermolysis bullosa

Recent News & Research

No recent news articles indexed yet for Dystrophic epidermolysis bullosa.
Search PubMed for Dystrophic epidermolysis bullosa

Browse all Dystrophic epidermolysis bullosa news →

Specialist Network

Top 6 by expertise

View all Dystrophic epidermolysis bullosa specialists →

Quick Actions